ReviewCancer letters2012
Recent trends in antibody-based oncologic imaging.
Review in Cancer letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Optical and Optoacoustic Imaging Probes.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [European journal of nuclear medicine and molecular imaging · 2025Article
- Emerging Head and Neck Tumor Targeting Contrast Agents for the Purpose of CT, MRI, and Multimodal Diagnostic Imaging: A Molecular Review.Diagnostics (Basel, Switzerland) · 2024Review
- Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Optical image-guided therapy of pancreatic cancer with an ultra-small bispecific protein.European journal of nuclear medicine and molecular imaging · 2023Article
- Near-infrared fluorescence imaging of hepatocellular carcinoma cells regulated by β-catenin signaling pathway.Frontiers in oncology · 2023Article
- The Need to Pair Molecular Monitoring Devices with Molecular Imaging to Personalize Health.Molecular imaging and biology · 2022Review
- Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies.International journal of molecular sciences · 2021Review
- Nanobodies asRSC chemical biology · 2021Review
- Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.Contrast media & molecular imaging · 2021Article
- Florescence Imaging Lung Cancer with a Small Molecule MHI-148.Journal of fluorescence · 2020Article
- Near-infrared fluorescence imaging in immunotherapy.Advanced drug delivery reviews · 2020Review
- Practical Guide for Quantification of In Vivo Degradation Rates for Therapeutic Proteins with Single-Cell Resolution Using Fluorescence Ratio Imaging.Pharmaceutics · 2020Article
- Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates.Biomaterials science · 2018Article
- Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging.Oncotarget · 2018Article
- Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.Clinical and experimental immunology · 2018Review
- Review
- Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers.Oncotarget · 2017Article
- Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.Alimentary pharmacology & therapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SERS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.